Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. - BAIN, V. G.; LEE, S. S.; PELTEKIAN, K.; YOSHIDA, E. M.; DESCHÊNES, M.; SHERMAN, M.; BAILEY, R.; WITT‐SULLIVAN, H.; BALSHAW, R.; KRAJDEN, M. (Alimentary Pharmacology & Therapeutics, 2008)